Pictet Asset Management (Switzerland)’s Krystal Biotech KRYS Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$50.4M	Sell	429,428 -202,965	-32%	-$20.7M	0.06%	289
2023 Q1	$50.6M	Buy	632,393 +6,414	+1%	+$504K	0.06%	280
2022 Q4	$49.6M	Sell	625,979 -98,223	-14%	-$7.29M	0.07%	274
2022 Q3	$50.5M	Sell	724,202 -20,904	-3%	-$1.51M	0.07%	264
2022 Q2	$48.9M	Buy	745,106 +56,551	+8%	+$3.52M	0.07%	281
2022 Q1	$45.8M	Sell	688,555 -12,848	-2%	-$802K	0.05%	331
2021 Q4	$49.1M	Buy	701,403 +63,911	+10%	+$3.72M	0.05%	340
2021 Q3	$33.3M	Buy	+637,492	New	+$37.7M	0.04%	412

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s KRYS Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Krystal Biotech (KRYS) stake by 32% in Q2 2023, selling an estimated $20.7M and leaving 429,428 shares worth $50.4M. The position accounts for 0.06% of the portfolio, ranked #289.

Pictet Asset Management (Switzerland) first reported a position in KRYS in Q3 2021 and has held it in 8 quarters since. The position peaked at $50.6M in Q1 2023. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

Pictet Asset Management (Switzerland) held 429,428 shares of Krystal Biotech worth $50.4M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 202,965 Krystal Biotech shares in Q2 2023, an estimated $20.7M.
Krystal Biotech made up 0.06% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #289 holding.
Pictet Asset Management (Switzerland) first reported a position in Krystal Biotech in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Krystal Biotech position peaked at $50.6M in Q1 2023.
183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.